Q-omics provides the consensus-scored MYL3 profile across patient tissues and cancer cell-line models. MYL3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MYL3 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, MYL3 protein abundance shows 22,110 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, KIRC, and LUAD as cancer lineages where MYL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYL3 survival associations across molecular data types. MYL3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYL3 RNA expression–survival associations across cancer types. High MYL3 expression shows unfavorable associations in BLCA, LUSC and COAD, but favorable associations in KIRP, KIRC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MYL3 RNA expression.
This table summarizes MYL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYL3 shows lower tumor expression in KIRC, KICH, LUAD, BLCA, HNSC and STAD. The KIRC box plot shows higher MYL3 RNA expression in normal versus tumor tissue (log2 FC = −1.656, t-test p < 0.001).
This table shows molecular features associated with MYL3 in patient tissues and cancer cell lines. In patient samples, MYL3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MYL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
